StemCell Therapy

Included in top indexing databases and has an impact factor of 3.104! The journal website is hosted on http://www.nature.com that gets 8.4 million page views per month Over 69,000 table of contents registrants and 82,706 page views across the Gene Therapy web site on average Easy and quick online submission system Rapid and rigorous peer review Advanced Article Preview (AAP) feature to be available from early March 2015 to all accepted original and review article authors. Accepted articles to be available online within 72 hours of acceptance into production! For further information on AAP please refer to About accepted article preview section Free manuscript deposition service to Pub Med Central on behalf of non-open access authors We regularly promote content alongside that of the Nature branded titles on our subject pages and in collections as well as via social media We also have a number of regional websites reaching a wide and varied audience demographic http://www.nature.com/regions Free online issue

Volume 22, No 7 July 2015 ISSN: 0969-7128 EISSN: 1476-5462

2014 Impact Factor 3.104* 117/289 Biochemistry & Molecular Biology 47/162 Biotechnology & Applied Microbiology 63/167 Genetics & Heredity 43/123 Medicine, Research & Experimental

Editors: J Glorioso, USA N Lemoine, UK

*2014 Journal Citation Reports Science Edition (Thomson Reuters, 2015)

Download the presentation from our How to Get Published Session. (281 kB)

Open

Gene Therapy now offers authors the option to publish their articles with immediate open access upon publication. Open access articles will also be deposited on PubMed Central at the time of publication and will be freely available immediately. Find out more from our FAQs page.

Reviews by top researchers in the field. See the recent Progress and Prospects articles.

Essential topics explored in depth in Gene Therapy Special Issues.

More:
Gene Therapy - Nature

This entry was posted on July 2, 2015 at 10:42 am and is filed under Gene therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |